Chronic Obstructive Pulmonary Disease

Engaged disease management

Remote COPD care

Quality of life for COPD patients and the cost of care are closely linked to how well the disease is managed. Recognition of early COPD exacerbation and faster intervention correlates with better outcomes. 

With Remote Monitoring patients can answer daily questions on their wellbeing in the comfort of their own home. And with medical device integration the Remote Patient Monitoring solution enables the caregiver to view vitals like oxygen saturation, spirometry, respiratory rate and heart rate in real time. These biomarkers have been identified as useful for early detection of exacerbation. This can lead to a decrease in the economic and clinical burden of COPD and improve patients’ abilities to self-manage. See the research

Benefits for healthcare providers

  • Enable early detection of exacerbation
  • Reduce ER visits and hospitalizations
  • Facilitate patient communication
  • Optimize use of care resources

Benefits for patients

  • Empower own disease management
  • High level of assurance and comfort
  • Reduce hospitalization
  • Easy and quick access to healthcare professionals

Research

Follow-up with Telemedicine in Early Discharge for COPD Exacerbations: Randomized Clinical Trial

COPD: Journal of Chronic Obstructive Pulmonary Disease, Dec 2020

Compared to the conventional home follow up, the telemonitoring procedure shows a slight advantage in relation to costs, but the greatest benefit is the evident optimization of the use of care resources. Here the telemonitored procedure increases the capacity to attend patients in home hospitalization for early discharge while maintaining the same quality of care.

Read More

Challenges and opportunities for telehealth in the management of chronic obstructive pulmonary disease: A qualitative case study in Greece

BMC Medical Informatics and Decision Making, Sep 2020

The case study outlines how telehealth opportunities are recognized as providing better bi-directional communication between caregiver and patient and as an effective tool for reassuring patients

Read More

A Remote Patient Monitoring Intervention for Patients With Chronic Obstructive Pulmonary Disease and Chronic Heart Failure

JMIR Cardio, Sep 2018

This study represents a piece of evidence to support the potential value of RPM among patients with COPD or CHF. This intervention shows a potential 68% reduction in ER visits and a 35% reduction in hospitalizations between the 3-month pre- and 3-month postintervention period.

Read More

Remote Patient Monitoring for the Detection of COPD Exacerbations

NCBI, Aug 2020

Exacerbations were best predicted by FVC and FEV1 below the one-sided 95% confidence interval derived from SPC but also by increased use of inhaled short-acting bronchodilators and fall in oxygen saturation. An RPM program that captures these parameters may be used to guide appropriate interventions aimed at reducing healthcare utilization in COPD patients.

Read More
Strategic Partnership

Secure and qualified oxygen therapy at home

Through our partnership with O2matic we can offer a combination of oxygen treatment for patients at home and Remote Patient Monitoring. This allows healthcare professionals to quickly detect worsening of their patient’s condition while increasing patient safety and quality of life. 

O2matic HOT 100 monitors and titrates oxygen based on the patient’s condition and optimizes oxygen treatment by regulating the oxygen supply based on a frequent measurement of the blood oxygen content. HOT 100 is connected to the patient’s existing oxygen source in the home, e.g. concentrator or bottle, and the patient’s preferred nasal catheter or mask.

Visit O2matic.com for more information

Address

Levvel Health ApS
Savsvinget 7, DK-2970 Hørsholm, Denmark
+45 7071 3383
contact@levvel.health

VAT NO.: 41230134

Follow us

Free Icon | Linkedin logo      Facebook Logo Icon of Glyph style - Available in SVG, PNG, EPS, AI & Icon fonts      Twitter icon

Co-funded

European Union's Horizon 2020 research and innovation programme | TiamatCo-funded by the Horizon 2020 of the European Union